Mark Bustoros, MD, Weill Cornell Medicine, New York City, NY, discusses a study that used whole-exome and RNA sequencing to evaluate molecular characteristics in patients with smoldering multiple myeloma (SMM). Three subgroups of SMM associated with increased risk of disease progression were identified, and Dr Bustoros elaborates on how this research may improve risk stratification in this disease setting and aid clinicians in identifying high-risk patients early. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.